• 原料直供
• 试剂商城
• 直接询价

分类

• Pharmaceuticals
• Intermediates & Fine Chemicals
• Sulfur & Selenium Compounds,

产品应用

• It is a non-ergot dopamine agonist drug and is indicated for the treatment of Parkinson?s disease.

相关文献及参考

• [2]. Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86.
• [3]. Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91.
• [4]. Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP? and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86.
• ########
• [1]. Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35.
• [1]. Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35.
• [2]. Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of